Five-Year Drug Survival and Discontinuation Reasons for Eight Biological Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Retrospective Analysis of 1182 Patients from the Niigata Orth
3 hours ago
- #drug survival
- #bDMARDs
- #rheumatoid arthritis
- Study analyzed 5-year drug survival and discontinuation reasons for eight bDMARDs in rheumatoid arthritis patients.
- Retrospective analysis included 1182 patients (784 naïve, 398 switch) from the Niigata Orthopedic Surgery Rheumatoid Arthritis Database (NOSRAD).
- Five-year drug survival varied: highest for tocilizumab (50.8%) in naïve and abatacept (42.6%) in switch cohorts.
- Discontinuation reasons included inadequate response (27.1%), non-adverse events (25.3%), and adverse events (17.3%).
- Predictors of discontinuation in naïve patients: male sex, lower baseline DAS28-ESR, absence of methotrexate co-therapy.
- Tocilizumab and abatacept showed highest retention rates in naïve and switch cohorts, respectively.
- Early, individualized drug selection and dose optimization are crucial for long-term bDMARD effectiveness.